Health Care Technology
Company Overview of Collaborative Drug Discovery, Inc.
Collaborative Drug Discovery, Inc. provides Web-based software platforms that organize preclinical research data for scientists to develop new drug candidates for commercial and humanitarian markets. The company’s database enables scientists to archive, mine, and collaborate around preclinical chemical and biological drug discovery data. Its platform comprises CDD Vault, which is used for storing and handling sensitive and private data; CDD Collaborate for enabling secure private-to-private collaborations with new selective projects views; and CDD Public, which is a set of growing public datasets from the scientific community. The company also offers software development, data curation, and ...
1633 Bayshore Highway
Burlingame, CA 94010
Founded in 2004
Key Executives for Collaborative Drug Discovery, Inc.
Vice President of Development
Director of Collaborations
Director of Product Management
Compensation as of Fiscal Year 2013.
Collaborative Drug Discovery, Inc. Key Developments
Collaborative Drug Discovery, Inc. Presents at The 2nd Annual Drug Repositioning and Indications Discovery Conference, Oct-24-2012 11:05 AM
Oct 3 12
Collaborative Drug Discovery, Inc. Presents at The 2nd Annual Drug Repositioning and Indications Discovery Conference, Oct-24-2012 11:05 AM. Venue: Hilton San Francisco Airport Bayfront, 600 Airport Blvd., Burlingame, CA 94010, United States. Speakers: Barry A. Bunin, Chief Executive Officer, President and Director.
NIAID Awards Second Grant to Collaborative Drug Discovery, Inc. and SRI International, Inc. to Continue Joint Development of Information Repository and Software
Aug 16 12
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a second grant to Collaborative Drug Discovery, Inc. and SRI International, Inc. to continue joint development of an information repository and software to identify novel therapeutics for tuberculosis (TB). The Phase II Small Business Technology Transfer Research (STTR) grant will support the next two years of research and focus on extending a systems biology-cheminformatics approach to develop molecular mimics and computationally evaluate them for drug efficacy. CDD and SRI researchers will further evaluate molecules discovered in Phase I, expand the scope of search for lead molecules for TB, and develop a software product for bioscience research use. The software will provide powerful query and analysis capabilities, and include links to other drug discovery tools and databases.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries